Centrexion Therapeutics Announces Highly Statistically Significant Topline Results from Phase 2b Study of CNTX-4975 in Patients with Knee Osteoarthritis Pain

Centrexion Therapeutics, a company focused on advancing the treatment of chronic pain with one of the largest exclusively pain-focused pipelines of non-opioid therapies in active development, today announced positive topline data from its Phase 2b study of CNTX-4975 in patients with knee osteoarthritis (OA) pain.

This entry was posted in Recent Development News: Q4 - 2016, Recent Developments. Bookmark the permalink.
Read Full Article »